Navigation Links
FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
Date:5/28/2008

TIRAT CARMEL, Israel, May 28 /PRNewswire/ --

- Study Will Compare Birth Rates of Women who Underwent Non-Invasive MRgFUS to Those who had Invasive Fibroid Surgery

InSightec Ltd. announced today that the U.S. Food and Drug Administration (FDA) cleared the company to conduct a clinical trial to evaluate the efficacy and safety of the ExAblate(R) 2000 system utilizing MR-guided Focused Ultrasound Surgery (MRgFUS) for the enhancement of fertility in women with non-hysteroscopically resectable uterine fibroids who are diagnosed with unexplained infertility.

Twenty U.S. and international sites will enroll a total of 650 women with uterine fibroids who are diagnosed with unexplained infertility. Half the women will undergo treatment with the ExAblate system, while the other half will have their fibroids surgically removed.

The study will measure the safety of each procedure, including pregnancy and delivery-related complications. The main efficacy goal of the trial will be to measure which procedure leads to a higher percentage of healthy live births resulting from pregnancies three to 15 months after treatment. Researchers will also examine the cost of treatment and any additional clinically required medical encounters and/or medications outside the study visits.

"While the link between uterine fibroids and infertility isn't fully understood, many women with uterine fibroids and infertility give birth to healthy babies after having their fibroids surgically removed," said Elizabeth A. Stewart, MD, a reproductive endocrinologist and Professor of Obstetrics and Gynecology at Mayo Clinic in Rochester, Minnesota. "The non-invasive ExAblate system precisely targets fibroid tissue without causing damage to the surrounding healthy areas, suggesting that it may be a safe approach for women with fibroids who want to preserve their fertility."

Accumulating clinical evidence shows that women have been able to conceive and successfully
'/>"/>

SOURCE InSightec Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
2. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
3. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
4. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... marzo 2015  SI-BONE, Inc., una società per ... fusione con chirurgia mininvasiva (minimally invasive surgical/MIS) per ... System ® , ha annunciato oggi che oltre ... intero utilizzando oltre 44.000 iFuse Implants.  ... adottata guadagnando consenso con oltre 900 chirurghi che ...
(Date:3/2/2015)... March 2, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... $15 million milestone payment from GSK related to advancing the ... familial amyloid polyneuropathy (FAP).  "We are very ... , and plan to report data from the Phase 2/3 ... fifteen months of dosing and are now receiving ISIS-TTR Rx ...
(Date:3/2/2015)... 2, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... developing breakthrough treatments for human disease, will release its ... Wednesday, March 4, 2015 before the financial markets open.  ... to discuss clinical development progress and financial results for ... 10:00 a.m. Eastern Time on March 4, 2015. ...
Breaking Medicine Technology:SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 2SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 3SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 4Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 2Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx 3Lexicon To Report Fourth Quarter And Year End 2014 Financial Results On March 4, 2015 2
... MORRISVILLE, N.C., Sept. 11 Clinical Logistics is pleased to announce ... Corporation (Gentris), a GLP compliant laboratory, located in Morrisville, North Carolina. ... DNA, RNA, whole blood, FFPE tissue blocks, urine, plasma, serum, saliva, ... storage conditions is available: , , ...
... YORK, Sept. 11 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova ... method for destroying breast cancer cells, using stem cell ... that enables us to identify the protein expression in ... tumors. This ability to identify the molecular markers of ...
Cached Medicine Technology:Clinical Logistics Enters Partnership with Gentris Corporation 2New stem cell identification technology could cure breast cancer 2
(Date:3/2/2015)... 2015 Representatives with BNatrl ( ... launched a multivitamin supplement that’s specifically designed for ... for BNatrl, said the multivitamin, which launched Jan. ... other world-class athletes. , "Being an avid marathon ... whole food multivitamin to improve my performance,” said ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... TX (PRWEB) March 02, 2015 What ... How should physicians request references? When are interviews scheduled, ... analyze employment opportunities?, Both training and practicing physicians who ... to these questions and more at the PracticeLink Physician ... 18. The drop-in Job Fair is from 5:30 to ...
(Date:3/2/2015)... Final Cut Pro X plugin specialists have ... Film Studios. , “The TranStatic Volume 2 plugin gives users ... CEO of Pixel Film Studios. “TranStatic Volume 2 is a ... editors toolbox.” , With TranStatic Volume 2 users can transition ... scrambling effects from Pixel Film Studios. Users have total control ...
(Date:3/1/2015)... Excellence is pleased to announce the addition of a digital ... are over 75 terms and phrases available for viewing, with more ... patients a better understanding of what our Providers are talking about ... With this resource, our patients are able to go back to ... that they may not remember or comprehend at the time of ...
Breaking Medicine News(10 mins):Health News:Bnatrl Launches Multivitamin Supplement for Runners 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2
... of brain tumor , , MONDAY, June 2 (HealthDay News) -- ... malignant brain tumor that was diagnosed last month. , The ... an especially lethal type of brain tumor, at Duke University ... Massachusetts Democrat,s office said he would be operated on by ...
... in 81 years the International Congress of Genetics takes place ... Nobel Prize winners get together with more than 2000 scientists ... genome analysis. The congress, which takes place for the 20th ... also being Berlin. Congress Chairman is Prof. Rudi Balling, Scientific ...
... PETERSBURG, Fla., June 2 The Advanced,Wound Management Division ... that its negative pressure wound therapy (NPWT) products will ... included in the,first phase of the competitive bidding program ... in the U.S. The program, which is,scheduled to take ...
... completed ... phase I studies, SAN ... of a worldwide exclusive agreement entered into in Feb,2008, GlaxoSmithKline (GSK) ... original agreement, GSK has rights to develop,manufacture and commercialize FLAP (5-Lipoxygenase ...
... Imagine being able to communicate,your practice,s message to ... practice growth and development. That is the focus of ... parent company of JG Pads, a pharmaceutical sales,support company ... United States since 1993. Because of its success, MarketHATCH ...
... Scientists at the University of Liverpool have found that ... antibiotics, suggesting that the infection is unlike the bacteria ... resistant to antibiotics and can sometimes go undetected in ... spread to humans. The team tested the strains found ...
Cached Medicine News:Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 2Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 3Health News:Sen. Kennedy Undergoing Surgery for Brain Tumor 4Health News:6 Nobel Prize Winners at International Congress of Genetics 2Health News:6 Nobel Prize Winners at International Congress of Genetics 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline 2Health News:Ohio Company to Debut Turnkey Marketing Material During Florida National Dental Convention 2Health News:Salmonella in garden birds responsive to antibiotics 2
Take Performance to a Higher Level....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop plus system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic ...
... used to seal the arterial puncture site. Duett ... the arteriotomy and the tissue tract with a ... a balloon catheter and procoagulant - the Duett ... stop the bleeding. The Duett is unique in ...
Medicine Products: